Eledon Pharmaceuticals (ELDN) Competitors $3.11 +0.03 (+0.97%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$3.26 +0.15 (+4.69%) As of 07/7/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ELDN vs. REPL, PHAR, SANA, NUVB, AVBP, TRVI, ANAB, IMTX, DAWN, and MRVIShould you be buying Eledon Pharmaceuticals stock or one of its competitors? The main competitors of Eledon Pharmaceuticals include Replimune Group (REPL), Pharming Group (PHAR), Sana Biotechnology (SANA), Nuvation Bio (NUVB), ArriVent BioPharma (AVBP), Trevi Therapeutics (TRVI), AnaptysBio (ANAB), Immatics (IMTX), Day One Biopharmaceuticals (DAWN), and Maravai LifeSciences (MRVI). These companies are all part of the "pharmaceutical products" industry. Eledon Pharmaceuticals vs. Its Competitors Replimune Group Pharming Group Sana Biotechnology Nuvation Bio ArriVent BioPharma Trevi Therapeutics AnaptysBio Immatics Day One Biopharmaceuticals Maravai LifeSciences Eledon Pharmaceuticals (NASDAQ:ELDN) and Replimune Group (NASDAQ:REPL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability. Which has more risk and volatility, ELDN or REPL? Eledon Pharmaceuticals has a beta of -0.16, meaning that its share price is 116% less volatile than the S&P 500. Comparatively, Replimune Group has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500. Is ELDN or REPL more profitable? Replimune Group's return on equity of -57.98% beat Eledon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Eledon PharmaceuticalsN/A -79.54% -41.62% Replimune Group N/A -57.98%-45.21% Do institutionals and insiders believe in ELDN or REPL? 56.8% of Eledon Pharmaceuticals shares are held by institutional investors. Comparatively, 92.5% of Replimune Group shares are held by institutional investors. 12.3% of Eledon Pharmaceuticals shares are held by insiders. Comparatively, 8.8% of Replimune Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts prefer ELDN or REPL? Eledon Pharmaceuticals currently has a consensus target price of $9.00, suggesting a potential upside of 189.39%. Replimune Group has a consensus target price of $20.83, suggesting a potential upside of 115.89%. Given Eledon Pharmaceuticals' higher probable upside, equities research analysts plainly believe Eledon Pharmaceuticals is more favorable than Replimune Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eledon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Replimune Group 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Does the media favor ELDN or REPL? In the previous week, Replimune Group had 6 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 6 mentions for Replimune Group and 0 mentions for Eledon Pharmaceuticals. Replimune Group's average media sentiment score of 0.44 beat Eledon Pharmaceuticals' score of 0.00 indicating that Replimune Group is being referred to more favorably in the news media. Company Overall Sentiment Eledon Pharmaceuticals Neutral Replimune Group Neutral Which has higher earnings and valuation, ELDN or REPL? Replimune Group is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEledon PharmaceuticalsN/AN/A-$36.18M-$2.10-1.48Replimune GroupN/AN/A-$247.30M-$3.07-3.14 SummaryReplimune Group beats Eledon Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Get Eledon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELDN vs. The Competition Export to ExcelMetricEledon PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$184.44M$2.92B$5.53B$9.03BDividend YieldN/A2.44%5.24%4.07%P/E Ratio-1.4820.3027.1920.03Price / SalesN/A249.79413.88108.83Price / CashN/A41.7026.2128.59Price / Book1.577.397.925.55Net Income-$36.18M-$55.04M$3.17B$248.49M7 Day Performance11.47%2.51%1.78%4.87%1 Month Performance0.97%-0.21%1.26%6.63%1 Year Performance25.91%3.41%33.31%20.38% Eledon Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELDNEledon Pharmaceuticals2.5332 of 5 stars$3.11+1.0%$9.00+189.4%+24.9%$184.44MN/A-1.4810REPLReplimune Group4.1504 of 5 stars$9.65+2.7%$20.83+115.9%+19.0%$724.61MN/A-3.14210High Trading VolumePHARPharming Group2.7013 of 5 stars$10.47-1.0%$30.00+186.5%+28.8%$719.77M$297.20M-52.35280Gap DownSANASana Biotechnology2.5452 of 5 stars$3.10-2.8%$9.17+195.7%-39.1%$719.27MN/A-3.52380NUVBNuvation Bio3.5826 of 5 stars$2.08-0.5%$7.17+244.6%-31.4%$711.15M$7.87M-0.8960High Trading VolumeAVBPArriVent BioPharma1.7197 of 5 stars$20.17-2.9%$40.00+98.3%+8.4%$710.59MN/A-5.3540TRVITrevi Therapeutics3.2509 of 5 stars$5.95flat$20.88+250.8%+130.6%$697.89MN/A-13.2220ANABAnaptysBio2.2604 of 5 stars$23.45-1.3%$42.38+80.7%-5.3%$697.79M$91.28M-4.84100IMTXImmatics2.3921 of 5 stars$5.53-3.2%$14.67+165.2%-52.9%$694.05M$168.65M-32.53260Positive NewsDAWNDay One Biopharmaceuticals1.6934 of 5 stars$6.63-2.5%$30.57+361.1%-51.6%$689.27M$131.16M-9.3460Upcoming EarningsMRVIMaravai LifeSciences3.8588 of 5 stars$2.60-2.6%$6.64+155.3%-62.8%$679.94M$259.18M-2.28610Positive News Related Companies and Tools Related Companies REPL Competitors PHAR Competitors SANA Competitors NUVB Competitors AVBP Competitors TRVI Competitors ANAB Competitors IMTX Competitors DAWN Competitors MRVI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELDN) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredInstant Cash (in 4 clicks)Since 1973, Wall Street has quietly used a strange little pricing quirk to cash flow billions. Now, for the...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eledon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eledon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ELDN Stock Alerts